Effect of copayments on drug use in the presence of annual payment limits

American Journal of Managed Care

Volumn 13, Issue 6 II, 2007, Pages 328-334

  Kephart, George ^a   Skedgel, Chris ^a   Sketris, Ingrid ^a   Grootendorst, Paul ^c   Hoar, John ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Nova Scotia Department of Health   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CANADA; DRUG COST; DRUG USE; EXPECTATION; HEALTH CARE POLICY; HEALTH INSURANCE; INCOME; PRESCRIPTION; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

AGED; COST SHARING; DEDUCTIBLES AND COINSURANCE; DRUG UTILIZATION REVIEW; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NOVA SCOTIA; PRESCRIPTION FEES;

EID: 34250858339     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv. 2004;34:101-122.
2. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730-740.
3. Smith DG, Kirking DM. Impact of consumer fees on drug utilisation. Pharmacoeconomics. 1992;2:335-342.
4. Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ. 2005;14:909-923.
5. Adams AS, Soumerai SB, Ross-Degnan D. The case for a Medicare drug coverage benefit: a critical review of the empirical evidence. Annu Rev Public Health. 2001;22:49-61.
6. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28:964-978.
7. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA. 2001;286:1732-1739.
8. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Serv Res. 1997;32:103-122.
9. Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002;167:246-252.
10. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
11. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951-959.
12. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
13. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626-634.
14. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. Can J Clin Pharmacol. 2002;9:79-99.
15. Stuart B, Briesacher BA, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff (Millwood). 2005;24:1022-1031.
16. Angus DE, Karpetz HM. Pharmaceutical policies in Canada: issues and challenges. Pharmacoeconomics. 1998;14(suppl 1):81-96.
17. Ellis RP. Rational behavior in the presence of coverage ceilings and deductibles. RAND J Econ. 1986;17:158-175.
18. Moffitt R. The economics of kinked budget constraints. J Econ Perspect. 1990;4:119-139.
19. Wilkins R. PPCF+ Version 3G User's Guide (Geocodes/PPCF): Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files. Ottawa, Ontario: Statistics Canada; 2002.
20. Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002;55:833-841.
21. Nagpal S. Effect of the Omeprazole Benefit Guidelines: Evaluation of Health Policy. Halifax, Nova Scotia: Department of Community Health and Epidemiology, Dalhousie University; 1998.
22. Wadibia EC, Lucas BD, Hilleman DE, Mooss AN. Economic impact of inappropriate histamine2-receptor antagonist use. Clin Ther. 1997;19:1085-1091.
23. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98:51-58.
24. Gray J. Therapeutic Choices. 4th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2003.
25. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006;12:130-142.
26. Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J, Sommers E. The Effects of Changes in Co-Payment and Premium Policies on the Use of Prescription Drugs in the Nova Scotia Seniors' Pharmacare Program: Final Report. Ottawa, Ontario: Canadian Health Services Research Foundation; 2003.
27. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
28. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166:737-745.
29. Sketris IS, Metge CJ, Blackburn JL, et al. The use of the WHO anatomical therapeutic chemical/defined daily dose methodology in Canada. Drug Information J. 2004;38:15-27.
30. Greene WH. Econometric Analysis. 5th ed. Upper Saddle River, NJ: Prentice Hall; 2003.
31. STATA Statistical Software: Release 8.0. College Station, Tex: StataCorp LP; 2003.
32. Dor A, Encinosa W. Does Cost Sharing Affect Compliance? The Case of Prescription Drugs. Cambridge, England: National Bureau of Economic Research; 2004. Working paper 10737.
33. Pauly MV. Medicare drug coverage and moral hazard. Health Aff (Millwood). 2004;23:113-122.
34. Schneeweiss S, Maclure M, Dormuth C, Avorn J. Pharmaceutical cost containment with reference-based pricing: time for refinements. CMAJ. 2002;167:1250-1251.
35. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24(suppl 3):65-78.
36. Finkelstein MM. Ecologic proxies for household income: how well do they work for the analysis of health and health care utilization? Can J Public Health. 2004;95:90-94.
37. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol. 1998;148:475-486.